Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank14
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P14
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$-132.03M+2.6%
2024$-135.50M-58.7%
2023$-85.39M+30.5%
2022$-122.92M-41.3%
2021$-87.01M-129.3%
2020$296.71M+2415.1%
2019$-12.82M-61.8%
2018$-7.92M-